Back to results
US 2023/0147657 A1Published application
Chimeric antigen receptor specific for human cd45rc and uses thereof
AssigneesInserm (Institut National De La Sante Et De La Recherche Medicale), Nantes Universite
InventorsCarole GUILLONNEAU, Ignacio ANEGON
Life of this patent
Estimating the term…
Abstract
In the field of immunotherapy, a chimeric antigen receptor (CAR) specific for-human CD45RC. Also, the immune cells expressing this CAR and the use thereof as a medicament. In particular, the use of this CAR for preventing or treating CD45RChigh-related diseases (including autoimmune diseases, undesired immune responses, monogenic diseases, lymphoma or cancer), or graft-versus-host disease (GVHD).
Claims20
-34. (canceled)
A chimeric antigen receptor (CAR) specific for human CD45RC, wherein said CAR comprises:
- (a) at least one extracellular binding domain, wherein said binding domain binds to said human CD45RC,
- (b) optionally at least one extracellular hinge domain,
- (c) at least one transmembrane domain, and
- (d) at least one intracellular signaling domain, wherein the intracellular domain comprises at least one T cell primary signaling domain and optionally at least one T cell costimulatory signaling domain.
1 more element
Dependencies are inferred from the claim text.